Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Laurus Labs Ltd

| Audited Consolidated Financial Results for the Year Ended March 31, 2026

BULLISH SENTIMENT

Report Source

⬤30th Apr 26

Summary : Laurus Labs reports strong FY26 financial performance, declares dividend, and progresses strategic initiatives.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Cost of Materials Consumed FY26: 2,794.34 Crores.
  2. Consolidated Employee Benefits Expense FY26: 895.45 Crores.
  3. Standalone Cost of Materials Consumed FY26: 2,624.93 Crores.
  4. Standalone Employee Benefits Expense FY26: 757.86 Crores.
  5. Consolidated Revenue from Operations FY26: 6,812.90 Crores.
  6. Standalone Revenue from Operations FY26: 6,089.07 Crores.
  7. Consolidated Net Cash from Operating Activities FY26: 1,623.50 Crores.
  8. Consolidated Net Cash Used in Investing Activities FY26: (1,088.66) Crores.
  9. Standalone Net Cash from Operating Activities FY26: 1,384.95 Crores.
  10. Standalone Net Cash Used in Investing Activities FY26: (847.06) Crores.
  11. Consolidated Total Assets FY26: 10,511.19 Crores.
  12. Consolidated Total Equity FY26: 5,431.36 Crores.
  13. Standalone Total Assets FY26: 9,540.03 Crores.
  14. Standalone Total Equity FY26: 5,251.94 Crores.
  15. Both standalone and consolidated financial results are presented.

Corporate Overview

  1. India
  2. Germany
  3. South Africa
  4. Manufacture and sale of Pharmaceuticals
  5. Pharmaceuticals

Risk Factors

  1. Reliance on other auditors.
  2. Impact of new Labour Codes.
  3. Uncertainty in demerger approval.
  4. Materiality of financial misstatements.

Key Drivers

  1. Audited financial results approved.
  2. Interim dividend declared.
  3. Strategic investments in subsidiaries.
  4. Proposed demerger scheme.

Auditor’s Report

  1. Unmodified Opinion on Audited Consolidated Financial Results for FY26.
  2. Unmodified Conclusion on Limited Review for Q4 FY26.
  3. Reliance on other auditors for certain subsidiaries and joint ventures.

Board Commentary

  1. Approved 2nd Interim Dividend of Rs. 1.20/- (60%) per equity share of Rs. 2/- each for FY 2025-26.
  2. New Labour Codes impacted employee benefits, increasing expenses.
  3. Invested 35 Crores in Laurus Bio Private Limited.
  4. Invested 49 Crores in KRKA Pharma Private Limited (Joint Venture).
  5. Invested in Kurnool Renewables as an associate.
  6. Approved Composite Scheme of Arrangement for demerger of Laurus Synthesis Private Limited.

Corporate Governance

  1. Audit Committee reviewed and Board approved results.